Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Franklin Resources Inc.

Franklin Resources Inc. trimmed its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 15.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,177,195 shares of the company's stock after selling 222,660 shares during the quarter. Franklin Resources Inc. owned about 0.54% of Hims & Hers Health worth $21,684,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of HIMS. Nisa Investment Advisors LLC increased its position in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC grew its position in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after purchasing an additional 3,507 shares during the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health during the 2nd quarter valued at approximately $111,000. CWM LLC raised its holdings in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after buying an additional 1,054 shares during the last quarter. Finally, Quarry LP lifted its stake in shares of Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company's stock worth $113,000 after buying an additional 2,913 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Melissa Baird sold 58,750 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $19.57, for a total value of $1,149,737.50. Following the completion of the transaction, the chief operating officer now directly owns 630,166 shares in the company, valued at approximately $12,332,348.62. This represents a 8.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Oluyemi Okupe sold 9,868 shares of the company's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $19.96, for a total value of $196,965.28. Following the completion of the transaction, the chief financial officer now directly owns 195,988 shares in the company, valued at approximately $3,911,920.48. This trade represents a 4.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,085,157 shares of company stock worth $26,765,193 in the last three months. 17.71% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of research reports. Needham & Company LLC began coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a "buy" rating and a $24.00 price target for the company. TD Cowen reaffirmed a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Bank of America downgraded shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and dropped their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Morgan Stanley assumed coverage on shares of Hims & Hers Health in a report on Tuesday. They set an "overweight" rating and a $42.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $22.80.

Hims & Hers Health Stock Down 0.6 %

Shares of Hims & Hers Health stock traded down $0.16 on Friday, reaching $26.20. The company's stock had a trading volume of 17,248,361 shares, compared to its average volume of 10,078,416. Hims & Hers Health, Inc. has a 52-week low of $8.09 and a 52-week high of $35.02. The company has a market capitalization of $5.72 billion, a P/E ratio of 59.55 and a beta of 1.25. The stock has a 50-day moving average price of $25.78 and a 200-day moving average price of $21.27.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period last year, the company posted ($0.04) EPS. Hims & Hers Health's quarterly revenue was up 77.1% compared to the same quarter last year. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.